Cover Image
市場調查報告書

疫苗、佐劑的全球市場

Global Vaccine Adjuvants Market

出版商 Mordor Intelligence LLP 商品編碼 358230
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗、佐劑的全球市場 Global Vaccine Adjuvants Market
出版日期: 2016年01月01日 內容資訊: 英文
簡介

全球疫苗、佐劑的市場規模,2016年41億美元,2021年55億6500萬美元和,年複合成長率 (CAGR) 預計以6.3%的速度成長。

本報告提供全球疫苗、佐劑 (輔助劑) 的市場相關分析,技術、產品、市場概要和最新趨勢,主要的推動及阻礙市場要素,各類型、各作用機制、各地區的市場趨勢預測,市場競爭環境,主要企業等的相關調查。

第1章 簡介

第2章 分析方法

第3章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
    • 新興國家市場成長
  • 市場課題
    • 價格設定的問題
  • 波特的五力分析

第4章 市場明細

  • 各類型
    • 岩鹽為基礎的、佐劑
    • 界面活性劑 (皂素)
    • 乳膠
    • 微脂體
    • 碳水化合物佐劑
    • 細菌生產品
    • 非細菌組織 (鯊烯)
    • 細胞激素
    • 病毒體
    • TLR (Toll樣受體) 為基礎的佐劑
    • 粘膜佐劑
    • 其他
  • 各作用機制
    • 積極免疫活性劑
    • 電信業者
    • 媒液佐劑
  • 各地區
    • 北美 (美國,加拿大,墨西哥)
    • 歐洲 (英國,德國,法國,義大利,西班牙等)
    • 亞太地區 (日本,中國,印度,韓國,澳洲、紐西蘭等)
    • 其他的國家 (RoW)

第5章 競爭環境

  • 企業合併、收購 (M&A)
  • 協定、產業合作、產業聯盟
  • 新產品的銷售

第6章 企業簡介

  • Invivogen
  • Sigma Aldrich
  • Seppic
  • Oz Biosciences
  • Novavax
  • Adjuvatis
  • Adjuvance Technologies
  • Vaxliant
  • Vaxine

第7章 投資機會相關分析師的見解

第8章 市場未來展望

目錄

The global market for Vaccine Adjuvants was estimated to be worth USD 4,100 million, in the year 2016. It poised to reach USD 5,565 million by the end of 2021, growing at an estimated CAGR of 6.3% during the forecast period of 2016-2021. The Adjuvants are pharmacological or immunological agents that helps in synergizing and directing the adaptive immune response to vaccine agents. Adjuvants are generally classified based on their source, mechanism of action and physical or chemical properties. Adjuvants can be broadly classified into three groups that is active immunostimulants, carriers, and vehicle adjuvants.

Understanding the application of adjuvants is very imperative in analyzing the market dynamics. This study targets at gaining a detailed overview of the market dynamics of the contemporary market and during the forecast period for the vaccine adjuvants market. Adjuvants basically enhance the specific immune response against co-inoculated antigens.

The Adjuvants market in study has been segmented based on type and mechanism of action. The segmentation based on type includes Mineral Salt based adjuvants, Tensoactive agents, Emulsions, Liposomes, Carbohydrate adjuvants, Bacterial Products, Non-Bacterial organics (Squalene), Saponins, Cytokines, Virosomes, TLR based adjuvants, and Others. The report estimates the market value of the different type of adjuvants and forecast the market till 2021. The mineral salt based adjuvants includes the different aluminum based, calcium based and other salt based adjuvants. The tensoactive agents includes the extracts from plants like saponin. The emulsion adjuvants are oil in water or water in oil emulsions. Cytokines adjuvant are cytokines that has been adjoined with the vaccines. Carbohydrate adjuvants includes the inulin derived adjuvants, glucans, dextrans, lentinans and mannose and galactomannans and others. Bacterial products are the adjuvants derived from bacteria. Virosomes are consist of membrane lipids and Viral membrane proteins.

A holistic study of the market has been carried out by incorporating various factors extending from country-specific demographic conditions and business cycles to market specific microeconomic influences that were needed to analyse the future trends of this market.

Table of Contents

1. Introduction

  • 1.1. Report Description
  • 1.2. Study Deliverables
  • 1.3. Market Definition

2. Research Methodology

3. Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Expanding government recommendations for immunizations
    • 3.1.2. Advanced technological innovations
    • 3.1.3. Unmet vaccine market needs for certain diseases
    • 3.1.4. Increasing use of recombinant subunit and synthetic vaccines
  • 3.2. Market Restraints
    • 3.2.1. Side effects of adjuvants
    • 3.2.2. High toxicity adjuvants
    • 3.2.3. Stringent regulatory factors
    • 3.2.4. High R&D cost of developing a new adjuvant
  • 3.3. Market opportunity
    • 3.3.1. Growth in emerging economies
  • 3.4. Market Challenges
    • 3.4.1. Pricing issues
  • 3.5. Porters Five force analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of Buyers
    • 3.5.3. Degree of competition
    • 3.5.4. Threat of substitution
    • 3.5.5. Threat of New entrant

4. Market Segmentation

  • 4.1. By Type
    • 4.1.1. Mineral Salt based adjuvants
    • 4.1.2. Tensoactive agents (Saponins)
    • 4.1.3. Emulsions
    • 4.1.4. Liposomes
    • 4.1.5. Carbohydrate adjuvants
    • 4.1.6. Bacterial Products
    • 4.1.7. Non-Bacterial organics (Squalene)
    • 4.1.8. Cytokines
    • 4.1.9. Virosomes
    • 4.1.10. TLR based adjuvants
    • 4.1.11. Mucosal Adjuvants
    • 4.1.12. Others
  • 4.2. By mechanism of action
    • 4.2.1. Active immunostimulants
    • 4.2.2. Carriers
    • 4.2.3. Vehicle adjuvants
  • 4.3. By Geography
    • 4.3.1. North America
      • 4.3.1.1. USA
      • 4.3.1.2. Canada
      • 4.3.1.3. Mexico
    • 4.3.2. Europe
      • 4.3.2.1. UK
      • 4.3.2.2. Germany
      • 4.3.2.3. France
      • 4.3.2.4. Itally
      • 4.3.2.5. Spain
      • 4.3.2.6. Rest of Europe
    • 4.3.3. Asia-Pacific
      • 4.3.3.1. Japan
      • 4.3.3.2. China
      • 4.3.3.3. India
      • 4.3.3.4. South Korea
      • 4.3.3.5. Australia & New Zealand
      • 4.3.3.6. Rest of Asia Pacific
    • 4.3.4. Rest of the world

5. Competitive Landscape

  • 5.1. Mergers & Acquisitions
  • 5.2. Agreements, collaboration and partnerships
  • 5.3. New Product Launches

6. Company Profiles

  • 6.1. Invivogen
  • 6.2. Sigma Aldrich
  • 6.3. Seppic
  • 6.4. Oz Biosciences
  • 6.5. Novavax
  • 6.6. Adjuvatis
  • 6.7. Adjuvance Technologies
  • 6.8. Vaxliant
  • 6.9. Vaxine

7. Analyst Outlook for investment opportunity

8. Future outlook of the market

Back to Top